resiquimod has been researched along with 1,2-dioleoyloxy-3-(trimethylammonium)propane in 1 studies
| Studies (resiquimod) | Trials (resiquimod) | Recent Studies (post-2010) (resiquimod) | Studies (1,2-dioleoyloxy-3-(trimethylammonium)propane) | Trials (1,2-dioleoyloxy-3-(trimethylammonium)propane) | Recent Studies (post-2010) (1,2-dioleoyloxy-3-(trimethylammonium)propane) |
|---|---|---|---|---|---|
| 465 | 14 | 318 | 703 | 2 | 279 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bein, G; Groeger, S; Hackstein, H; Hansmann, L; von Wulffen, W | 1 |
1 other study(ies) available for resiquimod and 1,2-dioleoyloxy-3-(trimethylammonium)propane
| Article | Year |
|---|---|
Human monocytes represent a competitive source of interferon-alpha in peripheral blood.
Topics: Adult; Fatty Acids, Monounsaturated; Flow Cytometry; Fluorescent Dyes; Humans; Imidazoles; Immunophenotyping; Interferon-alpha; Lipopolysaccharide Receptors; Male; Monocytes; Oligodeoxyribonucleotides; Poly I-C; Quaternary Ammonium Compounds; Statistics, Nonparametric; Toll-Like Receptor 7 | 2008 |